HIV Gag p24 specific responses secreting IFN-γ and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load

Clinical Immunology

Volumn 131, Issue 2, 2009, Pages 277-287

  Ndongala, Michel L ^a   Peretz, Yoav ^b   Boulet, Salix ^a   Doroudchi, Mehrnoosh ^b   Yassine Diab, Bader ^b   Boulassel, Mohamed Rachid ^c   Rouleau, Danielle ^b   Tremblay, Cécile ^b   LeBlanc, Roger ^a   Routy, Jean Pierre ^a   Sékaly, Rafick Pierre ^b   Bernard, Nicole F ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

AIED; Dual color ELISPOT; HIV Gag p24 responses; HIV viremia

Indexed keywords

CYTOKINE; GAG PROTEIN; GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 2; PROTEOME; VIRUS PROTEIN; VIRUS RNA;

ACUTE DISEASE; ADULT; ARTICLE; CYTOKINE RELEASE; DISEASE COURSE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 63749103545     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.11.006     Document Type: Article

References (69)

1. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68 (1994) 6103-6110
2. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., and Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68 (1994) 4650-4655
3. Phillips A.N. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 271 (1996) 497-499
4. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., Nguyen P.L., Khoruts A., Larson M., Haase A.T., and Douek D.C. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200 (2004) 749-759
5. Mellors J.W., Kingsley L.A., Rinaldo Jr. C.R., Todd J.A., Hoo B.S., Kokka R.P., and Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122 (1995) 573-579
6. Mellors J.W., Rinaldo Jr. C.R., Gupta P., White R.M., Todd J.A., and Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (1996) 1167-1170
7. Kaufmann G.R., Cunningham P., Kelleher A.D., Zaunders J., Carr A., Vizzard J., Law M., Cooper D.A., and The Sydney Primary HIV Infection Study Group. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. J. Infect. Dis. 178 (1998) 1812-1815
8. Matano T., Shibata R., Siemon C., Connors M., Lane H.C., and Martin M.A. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72 (1998) 164-169
9. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., Racz P., Tenner-Racz K., Dalesandro M., Scallon B.J., Ghrayeb J., Forman M.A., Montefiori D.C., Rieber E.P., Letvin N.L., and Reimann K.A. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (1999) 857-860
10. Price D.A., Goulder P.J., Klenerman P., Sewell A.K., Easterbrook P.J., Troop M., Bangham C.R., and Phillips R.E. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 1890-1895
11. Allen T.M., O'Connor D.H., Jing P., Dzuris J.L., Mothe B.R., Vogel T.U., Dunphy E., Liebl M.E., Emerson C., Wilson N., Kunstman K.J., Wang X., Allison D.B., Hughes A.L., Desrosiers R.C., Altman J.D., Wolinsky S.M., Sette A., and Watkins D.I. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407 (2000) 386-390
12. Jones N.A., Wei X., Flower D.R., Wong M., Michor F., Saag M.S., Hahn B.H., Nowak M.A., Shaw G.M., and Borrow P. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J. Exp. Med. 200 (2004) 1243-1256
13. Karlsson A.C., Iversen A.K., Chapman J.M., de Oliveira T., Spotts G., McMichael A.J., Davenport M.P., Hecht F.M., and Nixon D.F. Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS ONE 2 (2007) e225
14. Li B., Gladden A.D., Altfeld M., Kaldor J.M., Cooper D.A., Kelleher A.D., and Allen T.M. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J. Virol. 81 (2007) 193-201
15. Goepfert P.A., Lumm W., Farmer P., Matthews P., Prendergast A., Carlson J.M., Derdeyn C.A., Tang J., Kaslow R.A., Bansal A., Yusim K., Heckerman D., Mulenga J., Allen S., Goulder P.J., and Hunter E. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J. Exp. Med. 205 (2008) 1009-1017
16. Allen T.M., and Altfeld M. Crippling HIV one mutation at a time. J. Exp. Med. 205 (2008) 1003-1007
17. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., Casazza J.P., Kuruppu J., Kunstman K., Wolinsky S., Grossman Z., Dybul M., Oxenius A., Price D.A., Connors M., and Koup R.A. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 (2002) 95-98
18. Mehandru S., Poles M.A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., Boden D., Racz P., and Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200 (2004) 761-770
19. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., and Walker B.D. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278 (1997) 1447-1450
20. Wilson J.D., Imami N., Watkins A., Gill J., Hay P., Gazzard B., Westby M., and Gotch F.M. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J. Infect. Dis. 182 (2000) 792-798
21. McNeil A.C., Shupert W.L., Iyasere C.A., Hallahan C.W., Mican J.A., Davey Jr. R.T., and Connors M. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13878-13883
22. Iyasere C., Tilton J.C., Johnson A.J., Younes S., Yassine-Diab B., Sekaly R.P., Kwok W.W., Migueles S.A., Laborico A.C., Shupert W.L., Hallahan C.W., Davey Jr. R.T., Dybul M., Vogel S., Metcalf J., and Connors M. Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J. Virol. 77 (2003) 10900-10909
23. Younes S.A., Yassine-Diab B., Dumont A.R., Boulassel M.R., Grossman Z., Routy J.P., and Sekaly R.P. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198 (2003) 1909-1922
24. Migueles S.A., and Connors M. The role of CD4(+) and CD8(+) T cells in controlling HIV infection. Curr. Infect. Dis. Rep. 4 (2002) 461-467
25. Lichterfeld M., Kaufmann D.E., Yu X.G., Mui S.K., Addo M.M., Johnston M.N., Cohen D., Robbins G.K., Pae E., Alter G., Wurcel A., Stone D., Rosenberg E.S., Walker B.D., and Altfeld M. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J. Exp. Med. 200 (2004) 701-712
26. Oxenius A., Price D.A., Easterbrook P.J., O'Callaghan C.A., Kelleher A.D., Whelan J.A., Sontag G., Sewell A.K., and Phillips R.E. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Natl. Acad. Sci. U. S. A 97 (2000) 3382-3387
27. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B.M., Eldridge R.L., Robbins G.K., D'Aquila R.T., Goulder P.J., and Walker B.D. Immune control of HIV-1 after early treatment of acute infection. Nature 407 (2000) 523-526
28. Harari A., Vallelian F., and Pantaleo G. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur. J. Immunol. 34 (2004) 3525-3533
29. Harari A., Vallelian F., Meylan P.R., and Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J. Immunol. 174 (2005) 1037-1045
30. Harari A., Dutoit V., Cellerai C., Bart P.A., Du Pasquier R.A., and Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211 (2006) 236-254
31. Dalod M., Fiorentino S., Delamare C., Rouzioux C., Sicard D., Guillet J.G., and Gomard E. Delayed virus-specific CD8+ cytotoxic T lymphocyte activity in an HIV-infected individual with high CD4+ cell counts: correlations with various parameters of disease progression. AIDS Res. Hum. Retroviruses 12 (1996) 497-506
32. Altfeld M., Rosenberg E.S., Shankarappa R., Mukherjee J.S., Hecht F.M., Eldridge R.L., Addo M.M., Poon S.H., Phillips M.N., Robbins G.K., Sax P.E., Boswell S., Kahn J.O., Brander C., Goulder P.J., Levy J.A., Mullins J.I., and Walker B.D. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193 (2001) 169-180
33. Alter G., Merchant A., Tsoukas C.M., Rouleau D., LeBlanc R.P., Cote P., Baril J.G., Thomas R., Nguyen V.K., Sekaly R.P., Routy J.P., and Bernard N.F. Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection. J. Infect. Dis. 185 (2002) 755-765
34. Lichterfeld M., Pantaleo G., and Altfeld M. Loss of HIV-1-specific T cell proliferation in chronic HIV-1 infection: cause or consequence of viral replication?. AIDS 19 (2005) 1225-1227
35. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., Lederman M.M., Benito J.M., Goepfert P.A., Connors M., Roederer M., and Koup R.A. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 (2006) 4781-4789
36. Jansen C.A., Van Baarle D., and Miedema F. HIV-specific CD4+ T cells and viremia: who's in control?. Trends Immunol. 27 (2006) 119-124
37. Goulder P.J., Altfeld M.A., Rosenberg E.S., Nguyen T., Tang Y., Eldridge R.L., Addo M.M., He S., Mukherjee J.S., Phillips M.N., Bunce M., Kalams S.A., Sekaly R.P., Walker B.D., and Brander C. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193 (2001) 181-194
38. Yu X.G., Addo M.M., Rosenberg E.S., Rodriguez W.R., Lee P.K., Fitzpatrick C.A., Johnston M.N., Strick D., Goulder P.J., Walker B.D., and Altfeld M. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J. Virol. 76 (2002) 8690-8701
39. Lichterfeld M., Yu X.G., Mui S.K., Williams K.L., Trocha A., Brockman M.A., Allgaier R.L., Waring M.T., Koibuchi T., Johnston M.N., Cohen D., Allen T.M., Rosenberg E.S., Walker B.D., and Altfeld M. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J. Virol. 81 (2007) 4199-4214
40. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., Reddy S., de Pierres C., Mncube Z., Mkhwanazi N., Bishop K., van der Stok M., Nair K., Khan N., Crawford H., Payne R., Leslie A., Prado J., Prendergast A., Frater J., McCarthy N., Brander C., Learn G.H., Nickle D., Rousseau C., Coovadia H., Mullins J.I., Heckerman D., Walker B.D., and Goulder P. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13 (2007) 46-53
41. Boulet S., Ndongala M.L., Peretz Y., Boisvert M.P., Boulassel M.R., Tremblay C., Routy J.P., Sekaly R.P., and Bernard N.F. A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses. J. Immunol. Methods 320 (2007) 18-29
42. Alter G., Hatzakis G., Tsoukas C.M., Pelley K., Rouleau D., LeBlanc R., Baril J.G., Dion H., Lefebvre E., Thomas R., Cote P., Lapointe N., Routy J.P., Sekaly R.P., Conway B., and Bernard N.F. Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection. J. Immunol. 171 (2003) 477-488
43. Martro E., Suligoi B., Gonzalez V., Bossi V., Esteve A., Mei J., and Ausina V. Comparison of the avidity index method and the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion, two methods using a single serum sample for identification of recent HIV infections. J. Clin. Microbiol. 43 (2005) 6197-6199
44. Janssen R.S., Satten G.A., Stramer S.L., Rawal B.D., O'Brien T.R., Weiblen B.J., Hecht F.M., Jack N., Cleghorn F.R., Kahn J.O., Chesney M.A., and Busch M.P. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 280 (1998) 42-48
45. Boulassel M.R., Spurll G., Rouleau D., Tremblay C., Edwardes M., Sekaly R.P., Lalonde R., and Routy J.P. Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis. J. Clin. Apher. 18 (2003) 55-60
46. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W., Van Baarle D., Kostense S., Miedema F., McLaughlin M., Ehler L., Metcalf J., Liu S., and Connors M. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3 (2002) 1061-1068
47. Harari A., Petitpierre S., Vallelian F., and Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103 (2004) 966-972
48. Pantaleo G., and Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat. Rev., Immunol. 6 (2006) 417-423
49. Zuniga R., Lucchetti A., Galvan P., Sanchez S., Sanchez C., Hernandez A., Sanchez H., Frahm N., Linde C.H., Hewitt H.S., Hildebrand W., Altfeld M., Allen T.M., Walker B.D., Korber B.T., Leitner T., Sanchez J., and Brander C. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J. Virol. 80 (2006) 3122-3125
50. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., Johnston M.N., Corcoran C., Wurcel A.G., Fitzpatrick C.A., Feeney M.E., Rodriguez W.R., Basgoz N., Draenert R., Stone D.R., Brander C., Goulder P.J., Rosenberg E.S., Altfeld M., and Walker B.D. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77 (2003) 2081-2092
51. Kaufmann D.E., Bailey P.M., Sidney J., Wagner B., Norris P.J., Johnston M.N., Cosimi L.A., Addo M.M., Lichterfeld M., Altfeld M., Frahm N., Brander C., Sette A., Walker B.D., and Rosenberg E.S. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 78 (2004) 4463-4477
52. Peretz Y., Alter G., Boisvert M.P., Hatzakis G., Tsoukas C.M., and Bernard N.F. Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline. J. Virol. 79 (2005) 4908-4917
53. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., and Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77 (2003) 4911-4927
54. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., and Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
55. Pantaleo G., and Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10 (2004) 806-810
56. Zimmerli S.C., Harari A., Cellerai C., Vallelian F., Bart P.A., and Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7239-7244
57. Betts M.R., Ambrozak D.R., Douek D.C., Bonhoeffer S., Brenchley J.M., Casazza J.P., Koup R.A., and Picker L.J. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75 (2001) 11983-11991
58. Sacha J.B., Chung C., Rakasz E.G., Spencer S.P., Jonas A.K., Bean A.T., Lee W., Burwitz B.J., Stephany J.J., Loffredo J.T., Allison D.B., Adnan S., Hoji A., Wilson N.A., Friedrich T.C., Lifson J.D., Yang O.O., and Watkins D.I. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178 (2007) 2746-2754
59. Cohen G.B., Gandhi R.T., Davis D.M., Mandelboim O., Chen B.K., Strominger J.L., and Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 10 (1999) 661-671
60. Ranki A., Lagerstedt A., Ovod V., Aavik E., and Krohn K.J. Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch. Virol. 139 (1994) 365-378
61. Schwartz O., Marechal V., Le Gall S., Lemonnier F., and Heard J.M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2 (1996) 338-342
62. Collins K.L., Chen B.K., Kalams S.A., Walker B.D., and Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391 (1998) 397-401
63. Altfeld M., and Allen T.M. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. Trends Immunol. 27 (2006) 504-510
64. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., Giangrande P., Luzzi G., Morgan B., Edwards A., McMichael A.J., and Rowland-Jones S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3 (1997) 212-217
65. Kelleher A.D., Long C., Holmes E.C., Allen R.L., Wilson J., Conlon C., Workman C., Shaunak S., Olson K., Goulder P., Brander C., Ogg G., Sullivan J.S., Dyer W., Jones I., McMichael A.J., Rowland-Jones S., and Phillips R.E. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193 (2001) 375-386
66. Leslie A., Kavanagh D., Honeyborne I., Pfafferott K., Edwards C., Pillay T., Hilton L., Thobakgale C., Ramduth D., Draenert R., Le Gall S., Luzzi G., Edwards A., Brander C., Sewell A.K., Moore S., Mullins J., Moore C., Mallal S., Bhardwaj N., Yusim K., Phillips R., Klenerman P., Korber B., Kiepiela P., Walker B., and Goulder P. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J. Exp. Med. 201 (2005) 891-902
67. Martinez-Picado J., Prado J.G., Fry E.E., Pfafferott K., Leslie A., Chetty S., Thobakgale C., Honeyborne I., Crawford H., Matthews P., Pillay T., Rousseau C., Mullins J.I., Brander C., Walker B.D., Stuart D.I., Kiepiela P., and Goulder P. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80 (2006) 3617-3623
68. Schellens I.M., Borghans J.A., Jansen C.A., De Cuyper I.M., Geskus I.R.B., Van Baarle D., and Miedema F. Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time. PLoS ONE 3 (2008) e2745
69. Streeck H., Brumme Z.L., Anastario M., Cohen K.W., Jolin J.S., Meier A., Brumme C.J., Rosenberg E.S., Alter G., Allen T.M., Walker B.D., and Altfeld M. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med. 5 (2008) e100